mRNA |
myricetin |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.008 |
mRNA |
GSK4112 |
CTRPv2 |
pan-cancer |
AAC |
0.098 |
0.008 |
mRNA |
piperlongumine:MST-312 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.094 |
0.009 |
mRNA |
lenalidomide |
FIMM |
pan-cancer |
AAC |
0.4 |
0.009 |
mRNA |
MS-275 |
FIMM |
pan-cancer |
AAC |
0.32 |
0.01 |
mRNA |
ML203 |
CTRPv2 |
pan-cancer |
AAC |
0.098 |
0.01 |
mRNA |
Lisitinib |
GDSC1000 |
pan-cancer |
AAC |
-0.09 |
0.01 |
mRNA |
ML210 |
CTRPv2 |
pan-cancer |
AAC |
0.084 |
0.01 |
mRNA |
navitoclax:piperlongumine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.091 |
0.01 |
mRNA |
ABT-737 |
CTRPv2 |
pan-cancer |
AAC |
0.092 |
0.01 |